Denis-Claude ROY

Denis-Claude Roy is a Full Professor in the Department of Medicine at the University of Montreal and Director of the University Institute of Hemato-Oncology and Cell Therapy. He leads the Center of Excellence in Cell Therapy and chairs CellCAN, Canada's Regenerative Medicine Network. His research focuses on immunobiology of stem cell transplantation, optimizing grafts for anticancer efficacy, and reducing GVHD risks. He has pioneered UM171-expanded cord blood transplantation and contributed to clinical trials in CAR-T therapy, photodynamic treatment, and donor lymphocyte infusion strategies. Key roles include scientific director of C3i (Cancer Immunotherapy Commercialization) and leadership in EBMT consensus guidelines for haploidentical transplants. His work bridges fundamental research (e.g., MiHA discovery) with translational applications, including multicenter trials for novel therapies.

Educations: Doctorate in Medicine (Université de Montréal), Postdoctoral fellowship in Tumor Immunology (Harvard University).

Research Themes: Immunology of leukemias/lymphomas, stem cell graft manipulation, photodynamic therapy, expansion of hematopoietic progenitors. Collaborations involve teams like IRIC and C3i. Notable outcomes include improved survival rates in UM171 trials and reduced GVHD via T-cell depletion strategies.

Labs/Teams: Cell Therapy Unit, IRIC, and C3i. Active in clinical trials evaluating ATIR101 and MiHA-targeted T cells. Over 334 publications span 20+ years of impactful work in hematology and immunotherapy.